Wall Street’s major averages closed Friday's trading session higher, as both the S&P 500 (SP500) and Nasdaq Composite ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

一年可减重超16%，副作用温和可控 ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

GLP-1药物已在治疗2型糖尿病和肥胖方面展现出卓越疗效。ADA年会上公布的最新进展显示， 新一代GLP-1药物正通过多种策略提升疗效、安全性和便捷性。

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.